Welcome to the Irish Medical Times website
This site is aimed at healthcare professionals.
Are you a healthcare professional?
NB: We use cookies to help personalise your web experience and comply with Irish healthcare law. Whatever your choice, you are agreeing to our use of cookies. Please close this browser tab if you don't want to proceed.
This site contains information, news and advice for healthcare professionals.
You have informed us that you are not a healthcare professional and therefore we are unable to provide you with access to this site.

July 1, 2016

Efficacy of continued alendronate for fractures in women

In the FIT Long Term Extension (FLEX) trial, ten years of alendronate (ALN) did not significantly reduce the risk of non-vertebral fractures (NVF), compared with five years of treatment.
However, continuing ALN reduced the risk of clinical, but not morphometric, vertebral fractures, regardless of baseline vertebral fracture status.

In previous studies, ALN efficacy for NVF prevention in women without prevalent vertebral fracture was limited to those with femoral neck (FN) T-score -2.5 and -2 (RR 1.41; 95% CI 0.75-2.66) (p for interaction 0.019).
Continuing alendronate for ten years instead of stopping after five years thus reduces non-vertebral fracture risk in women without prevalent vertebral fracture whose FN T-score, achieved after five years of ALN, is -2.
J Bone Miner Res. 2010 Jan 8